Compare EARN & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | ACHV |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.7M | 239.0M |
| IPO Year | 2013 | N/A |
| Metric | EARN | ACHV |
|---|---|---|
| Price | $5.28 | $4.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.88 | ★ $15.50 |
| AVG Volume (30 Days) | 323.8K | ★ 598.8K |
| Earning Date | 02-20-2026 | 11-06-2025 |
| Dividend Yield | ★ 18.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,893,000.00 | N/A |
| Revenue This Year | $8.43 | N/A |
| Revenue Next Year | $17.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 43.30 | N/A |
| 52 Week Low | $4.33 | $1.84 |
| 52 Week High | $6.86 | $5.78 |
| Indicator | EARN | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 44.93 |
| Support Level | $5.15 | $4.23 |
| Resistance Level | $5.34 | $4.86 |
| Average True Range (ATR) | 0.09 | 0.26 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 60.18 | 8.85 |
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.